This application claims the benefit of Korean Patent Application No. 10-2013-0148452, filed on Dec. 2, 2013, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference.
1. Field
The present disclosure relates to methods and apparatuses for analyzing genetic data of subjects, and more particularly, to methods and apparatuses for analyzing genetic data acquired from an image analysis device such as a high contact cell imaging device, a high content screening device, or a high throughput screening device.
2. Description of the Related Art
‘Genome’ refers to the entirety of an organism's genetic information. There are various technologies for sequencing a person's genome, such as a DNA chip and next generation sequencing technology, and next-next-generation-sequencing technology. Genetic information, such as nucleic acid sequencing or protein information, is analyzed to find genes expressing diseases such as diabetes and cancer, or to examine the relationship between genetic diversity and genetic characteristics of individuals. In particular, a person's genetic information is important for examining different symptoms, or genetic characteristics of the person related to progress of a disease. Therefore, the genetic information is crucial for understanding current and future disease-related information to prevent diseases, and for selecting an optimal treatment at the initial stage of a disease.
High-dimensional data, such as data obtained from microarrays, is used in clinical studies to derive a biomarker candidate group and generate a statistical prediction model of clinical response variables using the biomarker candidate group. The microarrays data are widely used to examine a survival rate of patients, recurrence of diseases, metastasis or non-metastasis of diseases, drug response, etc. Recently, Affymetrix Gene-Chip™ became the first microarray to be approved by the U.S. Food and Drug Administration (FDA) as a clinical diagnosis test kit, and Illumina is to receive the U.S. FDA's approval for clinical sequencing devices and the like. This shows that clinical studies may be conducted more diversely using high-throughput technologies such as microarrays and the like in the future.
Provided are methods and apparatuses for analyzing genetic data of subjects.
Provided is a computer readable recording medium on which a program for executing the methods are recorded.
Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.
According to an aspect of the present disclosure, a method of analyzing genetic data of a subject includes generating a plurality of bootstrap data sets having binary response variables related to a specific response, from the genetic data; determining a first bootstrap data set that represent the bootstrap data sets, based on distributions of the binary response variables; generating permutation null distributions by permutating the first bootstrap data set P (where P is a natural number) times; and calculating empirical power of the bootstrap data sets by testing respective levels of significance of the bootstrap data sets based on the permutation null distributions. The generating of the bootstrap data sets, the determining of the first bootstrap data set, the generating of the permutation null distributions, and the calculating of the empirical power are executed by at least one processor.
According to another aspect of the present disclosure, a non-transitory computer-readable recording medium having recorded thereon a program, which, when executed by a computer, performs the method of analyzing the genetic data of the subject.
According to another aspect of the present disclosure, a computing apparatus for analyzing genetic data of a subject includes a bootstrapping unit for generating a plurality of bootstrap data sets having binary response variables related to a specific response, from the genetic data; a determining unit for determining a first bootstrap data set that represents the bootstrap data sets, based on distributions of the binary response variables; a permutating unit for generating permutation null distributions by permutating the first bootstrap data set P (where P is a natural number) times; and a calculating unit for calculating empirical power of the bootstrap data sets by testing respective levels of significance of the bootstrap data sets based on the permutation null distributions.
These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings in which:
Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects of the present description. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.
Although not shown in
In order not to obscure features of the present embodiment, the genetic data analysis system 100 of
Nucleic acid of an individual, such as deoxyribonucleic acid (DNA), is a genetic material including genetic information, i.e., genes. The base sequence of the nucleic acid includes information regarding cells, tissues, etc. that form the individual. Therefore, studies on nucleic acid sequence information of a person are performed to understand life phenomena, develop new drugs, diagnose and prevent diseases, conduct human genetic research, and the like.
A clinical specimen of the patient is used in biological studies. The clinical specimen, which is obtained by biopsy, endoscopy, surgery, and the like, may be used in pathological diagnosis, and then, if the patient approves, may be used for research. Accordingly, clinical specimens are highly valuable and scarce in most cases. Thus, it is important to estimate an appropriate sample size depending on an objective of research. When an experiment is conducted with too many samples, not only may the samples be wasted, but also it is likely that clinically useless results will be derived. On the contrary, when an experiment is conducted with too few samples, it is likely that scientifically meaningless results will be derived. Since a human body needs to be tested in the medical and clinical fields, it may be unethical to unnecessarily recruit too many people and test using unproven methods, or to test too few people and fail to yield scientifically meaningful conclusions. Therefore, when an Institutional Review Board (IRB) reviews a research proposal, it is important that the sample size is estimated with a statistical basis.
When it is intended to predict prognosis such as clinical response variables related to diseases, drug response, etc. using a biomarker, it is necessary to analyze genetic data such as microarray data. However, genetic data analysis processes typically require many calculation steps. In particular, among the genetic data analysis processes, a bootstrap data generation process and a permutation data generation process require a large amount of computing resources.
For example, a bootstrap data generation process and a permutation data generation process have been performed using genetic data introduced in Gene-expression Profiles Predict Survival of Patients with Lung Adenocarcinoma by Beer et al. (2002). Elapsed times of execution of the processes are shown in Table 1.
When a single piece of bootstrap data is permutated 1,000 times, even if 12 central processing units (CPUs) are used for parallel calculation, an execution time is longer than 70 minutes. If 1,000 or more pieces of bootstrap data are generated when the genetic data is analyzed once, about 50 days (=70 min×1,000) are necessary. Therefore, if 1,000 pieces of permutation data are generated for each of the 1,000 or more pieces of bootstrap data, it will be impractical to analyze genetic data due to an excessively long execution time.
In the genetic data analysis system 100 according to the present embodiment, a method of reducing the time consumed during the numerous times permutation is performed is provided so as to reduce inefficiency due to the long execution time when analyzing the genetic data of the subject group 1 using the computing apparatus 10, as shown in Table 1. Hereinafter, operations and functions of the computing apparatus 10 according to the present embodiment will be described in detail.
Referring to
Referring to
Hereinafter, the operations and the functions of the computing apparatus 10 will be described with reference to
The data acquiring unit 110 acquires the genetic data of the subject group 1. As described above, the genetic data includes detection results of gene expression patterns or gene expression levels, and corresponds to results of detecting genetic information of the subject group 1 that is acquired using an image analysis device such as a high contact cell imaging device, a high content screening device, or a high throughput screening device.
The data acquiring unit 110 may acquire the genetic data of the subject group 1 from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI), or The Cancer Genome Atlas (TCGA) database of the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI). Alternatively, the data acquiring unit 110 may acquire the genetic data from results that are acquired by directly conducting experiments on a microarray. That is, data may be acquired using any methods as long as a subject, an objective, and a platform of the research are not modified.
As shown in Table 2, the genetic data of the subject group 1 may be acquired, for example, as data of gene expression amounts of genes a, b, and c of subjects A, B, and C, but the present embodiment is not limited thereto.
The first prediction model generating unit 1221 of the bootstrapping unit 122 pre-processes acquired genetic data before bootstrapping the genetic data of the subject group 1.
First, the bootstrapping unit 122 extracts some (e.g., of n number of people) genetic data as pilot data from among the genetic data of the subject group 1.
Pilot data M is defined by Equation 1 below, where n number of subjects each includes g number of genes, and xij is a gene expression amount of a jth gene of an ith subject.
M={(xi1, . . . , xig), i=1, . . . , n} [Equation 1]
The pilot data may include information regarding binary response variables that respectively correspond to the n number of subjects and are related to a specific condition or a specific response.
The specific condition or the specific response may be, for example, existence or non-existence of a tumor (cancer), lymph node metastasis +/−, or existence or non-existence of a drug effect, but is not limited thereto. The specific condition or the specific response may include various conditions or responses that may be used to determine +/− or existence or non-existence with respect to the provided data.
That is, the pilot data M may include gene expression data of the g number of genes of each of the n number of subjects, and the binary response variables that respectively correspond to the n number of subjects.
Binary response variables Yi that respectively correspond to the n number of subjects may be defined by Equation 2 below.
For example, in a drug response experiment, it may be assumed that a subject having a binary response variable of 0 is in a control group, and a subject having a binary response variable of 1 is in a treatment group. Alternatively, in a lymph node metastasis experiment, it may be assumed that a subject having a binary response variable of 0 corresponds to lymph node metastasis −, and a subject having a binary response variable of 1 corresponds to lymph node metastasis +. Alternatively, regarding a tumor, it may be assumed that a subject having a binary response variable of 0 is normal, and a subject having a binary response variable of 1 is in a tumor group. However, the present embodiment is not limited to the examples above.
The first prediction model generating unit 1221 generates a prediction model for predicting the binary response variables y1 in the pilot data, using the pilot data as in Equation 1. The prediction model may be generated using a logistic regression model. However, the present embodiment is not limited thereto, and the prediction model may be generated using other types of models or algorithms.
First, the first prediction model generating unit 1221 generates a prediction model using a univariate logistic regression model which uses each gene included in the pilot data as a single variable.
The first prediction model generating unit 1221 may use the univariate logistic regression model by normalizing the pilot data as in Equation 3 below.
Referring to Equation 3,
The first prediction model generating unit 1221 uses a generated univariate logistic regression model to calculate an effect size {circumflex over (β)}j and a probability value, which are obtained by testing the null hypothesis H0:βj=0, or each of the genes included in the pilot data.
The first prediction model generating unit 1221 uses respective p-values of the genes to determine a top t number of genes. The top t number of genes that are determined by the first prediction model generating unit 1221 may be genes that are greatly influential in determining whether the binary response variable is 0 or 1. Among the g number of genes, how many genes are to be determined as the top t number of genes by the first prediction model generating unit 1221 may vary according to the use environment of the genetic data analysis system 100 of the present embodiment.
The first prediction model generating unit 1221 generates a multivariate logistic regression model which determines the determined top t number of genes as independent variables. The multivariate logistic regression model will be described with reference to Equation 4 below.
Equation 4 is a multivariate logistic regression model for an ith patient, which is generated using the pilot data. Referring to Equation 4, {circumflex over (β)}=({circumflex over (β)}0, {circumflex over (β)}1, . . . , {circumflex over (β)}t) indicates coefficients of the multivariate logistic regression model of the top t number of genes, and X′=(X′1, . . . , X′t) indicates normalized gene expression amounts that correspond to the top t number of genes.
The coefficients {circumflex over (β)}=({circumflex over (β)}0, {circumflex over (β)}1, . . . , {circumflex over (β)}t) of the multivariate logistic regression model of the pilot data are used to determine binary response variables which will be included in bootstrap data sets to be described below.
When the first prediction model generating unit 1221 has finished generating the multivariate logistic regression model of the pilot data as in Equation 4, the bootstrapping unit 122 bootstraps the pilot data.
The re-sampling unit 1223 generates bootstrap gene expression data having N (where N is a natural number) number of samples using statistical properties of the pilot data and gene expression amounts that are extracted from the pilot data.
With respect to the pilot data M as defined in Equation 1, the re-sampling unit 1223 calculates a sample mean
As in Equation 5 below, the re-sampling unit 1223 generates a bootstrap data set {tilde over (M)} having N (where N>n) number of samples with respect to probability variables of εi, . . . , εN˜iidN(0,1).
i′ is randomly chosen number from (1, . . . , n)
When the pilot data M is given, conditional covariance of a bootstrap data set {tilde over (M)} is approximately equal to covariance of the pilot data M, which may be defined by Equation 6 below.
cov({tilde over (M)}|M)→cov(M), as n→∞ [Equation 6]
Following the processes described above, the re-sampling unit 1223 generates the bootstrap data set {tilde over (M)} using the pilot data M. However, the re-sampling unit 1223 only generates bootstrap gene expression data to be included in the bootstrap data set {tilde over (M)}, and the variable determining unit 1225 determines binary response variables to be included in the bootstrap data set {tilde over (M)}.
The variable determining unit 1225 determines the binary response variables in the bootstrap gene expression data using the bootstrap gene expression data {tilde over (M)} that is generated by the re-sampling unit 1223.
The variable determining unit 1225 calculates a risk score of the N number of samples included in the bootstrap data set {tilde over (M)} using the prediction model of the pilot data described with reference to Equation 4. The risk score of the N number of samples included in the bootstrap data set {tilde over (M)} may be calculated as in Equation 7 below.
Referring to Equation 7, {circumflex over (β)}=({circumflex over (β)}0, {circumflex over (β)}1, . . . , {circumflex over (β)}t) indicates the coefficients of the multivariate logistic regression model of the pilot data.
The variable determining unit 1225 calculates binary response variables y′i(i=1, . . . , N) that respectively correspond to the N number of samples in the bootstrap data set {tilde over (M)} using Bernoulli trials with probability {circumflex over (p)}i as in Equation 8 below.
y′i˜Bernoulli ({circumflex over (p)}i) [Equation 8]
As shown in Equation 9 below, the bootstrapping unit 122 generates bth bootstrap data set {circumflex over (M)}b that includes the bootstrap gene expression data {circumflex over (M)}={(zi1, . . . , zig), i=1, . . . , N} generated by the re-sampling unit 1223, and the binary response variables y′i(i=1, . . . , N) determined by the variable determining unit 1225.
{tilde over (M)}
b
={y′
i, (zi1, . . . , zig)} [Equation 9]
where i=(1, . . . , N), b=(1, . . . , B)
While the description above is about a case where the bootstrapping unit 122 performs a bootstrapping process once, Equation 9 describes a case where the bootstrapping unit 122 repeats the bootstrapping process B times to thus generate B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) that are different from each other.
The variable determining unit 1225 of the bootstrapping unit 122 generates the bootstrap data sets such that marginal-sums of the binary response variables y′i(i=1, . . . , N) in each of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) are the same.
Referring to
The bootstrapping unit 122 randomly extracts some among the genetic data 310 to generate the pilot data 320. The pilot data 320 may be data of various numbers of patients, for example, data of 30 patients (n=30) or data of 50 patients (n=50).
In a case where the pilot data 320 of 30 patients (n=30) is used, the bootstrapping unit 122 may use the pilot data 320 to generate B (e.g., B=1000) number of bootstrap data sets 330 having N (e.g., N=100) number of samples.
The bootstrap data sets 330 may each include data of predicted binary response variables y′i(i=1, . . . , N).
Since
Referring back to
Specifically, among the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B), the determining unit 124 determines a bootstrap data set that includes binary response variables y′i that are distributed with the highest frequency as the first bootstrap data set {tilde over (M)}b′.
As described above, the variable determining unit 1225 of the bootstrapping unit 122 generates the bootstrap data sets such that the marginal-sums of the binary response variables y′i(i=1, . . . , N) in each of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) are the same.
Hereinafter, the reason why the bootstrap data set that includes binary response variables y′i that are distributed with the highest frequency is determined as the first bootstrap data set {tilde over (M)}b′ is described.
For example, in a multivariate normal distribution (MVN) (0,Σ), where the average is 0 and there are 100 genes, simulation of genetic data having N number of samples is defined by Equation 10 below.
M
simul={(zi1, . . . , zi100), i=1, . . . , N} [Equation 10]
As defined in Equation 11 below, a covariance matrix is a block-diagonal matrix having a size of g x g, in which a size of a block corresponds to a 10×10 autocorrelation structure.
In the simulation genetic data Msimul defined as in Equations 10 and 11, 1,000 simulation bootstrap data sets {tilde over (M)}bsimul={yisimul, (zi1, . . . , zi100); i=1, . . . , N}, b=1, . . . , 1000, where n=30, p=100, ρ=0.5, N=50, and an effective size of the genes are β=0, may be generated. In this case, marginal-sums of binary response variables yisimul of the 1,000 simulation bootstrap data sets {tilde over (M)}bsimul may be distributed as shown in
Referring to
Since the effective size of the genes is β=0 in the 1,000 simulation bootstrap data sets {tilde over (M)}bsimul, a probability of Bernoulli trials for determining the binary response variable is defined as pi=½. Therefore, among the simulation bootstrap data sets {tilde over (M)}bsimul, a case that has the highest frequency is where there is a similar number of 0's and 1's among the 50 binary response variables yisimul.
After calculating a maximum likelihood estimator (MLE) of a non-centrality parameter (NCP) of a non-central χ2 distribution for each of the simulation bootstrap data sets {tilde over (M)}bsimul, a histogram of 1,000 NCPs shows normal distribution. Also, in comparison to cumulative density functions (CDFs) of permutation null distributions of the simulation bootstrap data sets {tilde over (M)}bsimul, a CDF of the non-central χ2 distribution having an average of the NCP of each of the simulation bootstrap data sets {tilde over (M)}bsimul passes the center of 1,000 permutation null distributions.
Accordingly, it may be assumed that, among the simulation bootstrap data sets {tilde over (M)}bsimul, a simulated bootstrap data set that includes binary response variables that are distributed with the highest frequency (for example, 115, as in
Referring back to
The permutating unit 126 generates permutation null distributions by permutating the first bootstrap data set {tilde over (M)}b′, which is determined by the determining unit 124, P (where P is a natural number) times.
Specifically, the permutation data generating unit 1261 generates P number of permutation data sets by permutating the first bootstrap data set {tilde over (M)}b′. High dimension data such as genetic data may be permutated by fixing data of gene expression amounts in the first bootstrap data set {tilde over (M)}b′, and then arbitrarily matching binary response variables with the data of gene expression amounts. Even when performing the permutation process as described above, respective marginal-sums of the P number of permutation data sets that are generated from the first bootstrap data set {tilde over (M)}b′ are the same.
Referring to
As described above, each of the permutation data sets 520 includes the same data of gene expression amounts. However, even when marginal-sums of binary response variables included in the permutation data sets 520 are the same, binary response variables that are included in each of the 1,000 permutation data sets 520 may be distributed as in
Referring back to
The k-fold cross-validation is performed by randomly classifying the P number of permutation data sets 520 into k-fold sets having approximately the same number of pieces of data, and then, using k-1 number of sets as training sets and the single remaining set as a testing set. The k-fold cross-validation is a method in which the above-described process is repeated k times to evaluate a prediction model that is formed in the training sets with respect to the testing set.
In the related art, when the k-fold cross-validation is performed, a data set may be repeatedly used as a training set or a testing set, and thus, a prediction model may be overfit.
In particular, when the k-fold cross-validation is performed on the bootstrap data sets {tilde over (M)} during a process of analyzing the genetic data, a bootstrap data set may be repeatedly used as a training set or a testing set and thus be overfit. In this regard, variation of test statistics of the bootstrap data sets {tilde over (M)} may be relatively large, or validity of a prediction model may be evaluated as being unstable.
In order to solve this problem, permutation may need to be performed. However, as described above, an excessively large amount of time may be required to generate the bootstrap data sets {tilde over (M)}, and permutation data sets for each of the bootstrap data sets {tilde over (M)}.
Instead of permutating the entire bootstrap data set {tilde over (M)}, the computing apparatus 10 according to the present embodiment permutates a single first bootstrap data set {tilde over (M)}b′ that represents the entire bootstrap data set {tilde over (M)}. Therefore, less amount of computing resources may be required, and it is possible to obtain an analysis result that is similar to an analysis result obtained by permutating the entire bootstrap data set {tilde over (M)}.
The null distribution analyzing unit 1265 performs a chi-square test to a result of k-fold cross-validation and calculates chi-square (χ2) statistics, and thus acquires permutation null distributions {χb′p2: p=1, . . . , P} of the first bootstrap data set {tilde over (M)}b′.
Since the first bootstrap data set {tilde over (M)}b′ represents the entire bootstrap data set {tilde over (M)}, the permutation null distributions {χb′p2: p=1, . . . , P} of the first bootstrap data set {tilde over (M)}b′ are regarded as respective permutation null distributions of the remaining bootstrap data sets excluding the first bootstrap data set {tilde over (M)}b′.
The calculating unit 128 calculates empirical power of the bootstrap data sets {tilde over (M)} by testing respective levels of significance of the bootstrap data sets {tilde over (M)} based on the permutation null distributions {χb′p2: p=1, . . . , P}.
Specifically, the second prediction model generating unit 1281 generates prediction models that respectively correspond to the bootstrap data sets {tilde over (M)} generated by the bootstrapping unit 122. Similar to the pilot data, the second prediction model generating unit 1281 generates a prediction model that corresponds to the bth bootstrap data set {tilde over (M)}b using a univariate logistic regression model and a multivariate logistic regression model. In this case, the prediction model may be for predicting the binary response variables y′i using gene expression amounts of N number of samples included in the bth bootstrap data set {tilde over (M)}b.
The probability value calculating unit 1283 may use various methods to calculate probability values that represent validity of the prediction models that respectively correspond to the bootstrap data sets {tilde over (M)}.
According to a first method, the probability value calculating unit 1283 calculates respective probability values pb of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) according to a distribution rate of chi-square test statistics χp2 of the P number of permutation data sets that are greater than a chi-square test statistic χb2 of the bth bootstrap data set {tilde over (M)}b. That is, the probability value calculating unit 1283 may use Equation 12 below to calculate the probability value pb.
According to a second method, the probability value calculating unit 1283 calculates the respective probability values pb of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) that correspond to a NCP, by fitting the chi-square test statistics χp2 of the P number of permutation data sets to the non-central χ2 distribution.
Specifically, a CDF of the non-central χ2 distribution has a probability density function (PDF) as in Equation 13 below.
where g(x; v) is a PDF of central χ2 distribution,
k is a degree of freedom(df), and λ is a non-centrality parameter
Afterward, the probability value calculating unit 1283 may estimate a NCP {circumflex over (λ)}mle using a maximum likelihood estimation that uses the permutation null distributions {χb′p2: p=1, . . . , P} of the first bootstrap data set {tilde over (M)}b′, and thus calculate the probability value pb as in Equation 14 below.
p
b=1−FX(χb2; k=1, {circumflex over (λ)}mle), [Equation 14]
where Fx is CDF of fX.
According to a third method, the probability value calculating unit 1283 calculates the respective probability values pb of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) by approximately calculating an estimated probability value (pb) of permutation performed P times according to an estimated probability value (pe) of permutation performed an infinite number of times.
Specifically, when the estimated probability value (pe) of permutation performed an infinite number of times is a true value, pe is approximately calculated by performing permutation 1,000 times. The true value pe may be defined by Equation 15 below, where D is the number of p-values that have extreme values during permutation performed P times.
Pt is the number of cases where all possible permutations have different statistics, and Dt is the number of cases where statistics have extreme values. A relationship between Pt and Dt is defined by Equation 16 below.
p
t
=Pr(Dt≦dt) [Equation16]
When {circumflex over (p)}=Dt/Pt in Equation 16, Dt follows a binary distribution where the number of trials is Pt and a probability for each trial is p∞, as in Equation 17 below.
D
t
={circumflex over (p)}·P
t
˜B(Pt, p∞), [Equation 17]
where p∞=Pr(χp2≧χb2)
A probability that Dt may have a specific value dt is defined by Equation 18 below.
Equation 18 indicates that a random variable Dt follows a discrete uniform distribution. Therefore, Equation 16 may be written as in Equation 19 below.
Referring to Equation 19, when Dt=dt, a distribution of D is P times of independent trials in which a probability of an extreme value each time permutation is performed equals pt. Thus, the distribution of D follows a binary distribution as in Equation 20 below.
D|(Dt=dt)˜B(P, pt) [Equation 20]
pe may be acquired using Equation 20 and Equation 21 below.
Based on pe that is calculated using a cumulative distribution F, the respective probability values Pb of the B number of bootstrap data sets {tilde over (M)}b (b=1, . . . , B) may be calcuated as in Equation 22 below, which uses an integral approximation method.
Specifically, according to the third method, the probability value calculating unit 1283 may calculate the probability value pb of permutation performed P times using the estimated probability value (pe) of permutation performed an infinite number of times.
The power calculating unit 1285 tests respective levels of significance of the respective probability values pb of the B number of bootstrap data sets {tilde over (M)}(b=1, . . . , B) based on the permutation null distributions generated from the first bootstrap data set {tilde over (M)}b′, and then calculates a distribution rate of bootstrap data sets that are determined to be valid among the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B).
Specifically, first, the power calculating unit 1285 generates an empirical distribution according to the permutation null distributions generated from the first bootstrap data set {tilde over (M)}b′. Then, the power calculating unit 1285 compares the respective probability values pb of the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B) to a predetermined level of significance α (for example, 5%) in the empirical distribution so as to test whether or not the bth bootstrap data set {tilde over (M)}b is valid.
For example, the power calculating unit 1285 may determine that the bth bootstrap data set {tilde over (M)}b is valid when a calculated probability value pb is equal to or less than the predetermined level of significance α, and is invalid when the calculated probability value pb is greater than the predetermined level of significance α.
The power calculating unit 1285 calculates empirical power of sample size N by calculating a distribution rate of bootstrap data sets that are determined to be valid based on the predetermined level of significance α among the B number of bootstrap data sets {tilde over (M)}b(b=1, . . . , B). The predetermined level of significance α may vary.
Accordingly, the power calculating unit 1285 may calculate empirical power (1−{circumflex over (β)}N), which is a test result of the sample size N, using Equation 23.
According to Equation 23, under the assumption that a target power (1−β) is 0.80, when the empirical power (1−{circumflex over (β)}N) of the sample size N exceeds 0.80, it is determined that the sample size N corresponds to an optimal sample size Nopt for performing an experiment or research related to a specific response or a specific condition. However, when the empirical power (1−{circumflex over (β)}N) of the sample size N is equal to or lower than 0.80, it is determined that the sample size N does not correspond to an optimal sample size Nopt.
In operation 610, the bootstrapping unit 122 generates the plurality of bootstrap data sets {tilde over (M)} having the binary response variables y′i related to a specific response, from the genetic data.
In operation 620, the determining unit 124 determines the first bootstrap data set {tilde over (M)}b′ that represents the bootstrap data sets {tilde over (M)}, based on distributions of the binary response variables y′i.
In operation 630, the permutating unit 126 generates the permutation null distributions {χb′p2: p=1, . . . , P} by permutating the first bootstrap data set {tilde over (M)}b′ P (where P is a natural number) times.
In operation 640, the calculating unit 128 calculates the empirical power of the bootstrap data sets {tilde over (M)} by testing the respective levels of significance of the bootstrap data sets {tilde over (M)} based on the permutation null distributions.
In general, statistical analysis methods that generate a plurality of permutation data sets so as to cross-validate a plurality of bootstrap data sets consume an excessively large amount of computing resources and have a long execution time. However, according to the above-described embodiments of the present disclosure, a plurality of permutation data sets that are generated from a single bootstrap data set representing the entire bootstrap data sets may be used to more quickly acquire an approximate result. Thus, it is possible to reasonably reduce a consumption amount of computing resources and the execution time.
In addition, other embodiments of the present disclosure can also be implemented through computer readable code/instructions in/on a medium, e.g., a computer readable medium, to control at least one processing element to implement any of the above described embodiments. The medium can correspond to any medium/media permitting the storage and/or transmission of the computer readable code.
The computer readable code can be recorded/transferred on a medium in a variety of ways, with examples of the medium including non-transitory recording media, such as magnetic storage media (e.g., ROM, floppy disks, hard disks, etc.) and optical recording media (e.g., CD-ROMs, or DVDs), and transmission media such as Internet transmission media. Thus, the medium may be such a defined and measurable structure including or carrying a signal or information, such as a device carrying a bitstream according to one or more embodiments of the present disclosure. The media may also be a distributed network, so that the computer readable code may be stored/transferred and executed in a distributed fashion. Furthermore, the processing element may include a processor or a computer processor, and processing elements may be distributed and/or included in a single device.
It should be understood that the exemplary embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.
While one or more embodiments of the present disclosure have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the following claims.
Number | Date | Country | Kind |
---|---|---|---|
10-2013-0148452 | Dec 2013 | KR | national |